Literature DB >> 29197677

Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation.

Caroline R Cantilena1, Sawa Ito2, Xin Tian3, Prachi Jain1, Fariba Chinian1, Prathima Anandi1, Keyvan Keyvanfar1, Debbie Draper1, Eleftheria Koklanaris1, Sara Hauffe1, Jeanine Superata1, David Stroncek4, Pawel Muranski1, A John Barrett1, Minoo Battiwalla1.   

Abstract

Various approaches have been developed for ex vivo T cell depletion in allogeneic stem cell transplantation to prevent graft-versus-host disease (GVHD). Direct comparisons of T cell depletion strategies have not been well studied, however. We evaluated cellular and plasma biomarkers in 2 different graft manipulation strategies, CD3+CD19+ cell depletion (CD3/19D) versus CD34+ selection (CD34S), and their associations with clinical outcomes. Identical conditions, including the myeloablative preparative regimen, HLA-identical sibling donor, GVHD prophylaxis, and graft source, were used in the 2 cohorts. Major clinical outcomes were similar in the 2 groups in terms of overall survival, nonrelapse mortality, and cumulative incidence of relapse; however, the cumulative incidence of acute GVHD trended to be higher in the CD3/19D cohort compared with the CD34S cohort. A distinct biomarker profile was noted in the CD3/19D cohort: higher levels of ST2, impaired Helios- FoxP3+Treg reconstitution, and rapid reconstitution of naïve, Th2, and Th17 CD4 cells in the early post-transplantation period. In vitro graft replication studies confirmed that CD3/19D disproportionately depleted Tregs and other CD4 subset repertoires in the graft. This study confirms the utility of biomarker monitoring, which can be directly correlated with biological consequences and possible future therapeutic indications. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarkers; Ex vivo T cell depletion; Graft manipulation

Mesh:

Substances:

Year:  2017        PMID: 29197677      PMCID: PMC6182775          DOI: 10.1016/j.bbmt.2017.11.028

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

1.  An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Authors:  Matthew J Hartwell; Umut Özbek; Ernst Holler; Anne S Renteria; Hannah Major-Monfried; Pavan Reddy; Mina Aziz; William J Hogan; Francis Ayuk; Yvonne A Efebera; Elizabeth O Hexner; Udomsak Bunworasate; Muna Qayed; Rainer Ordemann; Matthias Wölfl; Stephan Mielke; Attaphol Pawarode; Yi-Bin Chen; Steven Devine; Andrew C Harris; Madan Jagasia; Carrie L Kitko; Mark R Litzow; Nicolaus Kröger; Franco Locatelli; George Morales; Ryotaro Nakamura; Ran Reshef; Wolf Rösler; Daniela Weber; Kitsada Wudhikarn; Gregory A Yanik; John E Levine; James Lm Ferrara
Journal:  JCI Insight       Date:  2017-02-09

2.  Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

Authors:  M A Diaz; A Pérez-Martínez; B Herrero; N Deltoro; I Martinez; M Ramirez; L Abad; J Sevilla; E Merino; J Ruiz; J L Vicario; M Gonzalez-Vicent
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

3.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

Authors:  John E Levine; Thomas M Braun; Andrew C Harris; Ernst Holler; Austin Taylor; Holly Miller; John Magenau; Daniel J Weisdorf; Vincent T Ho; Javier Bolaños-Meade; Amin M Alousi; James L M Ferrara
Journal:  Lancet Haematol       Date:  2014-12-23       Impact factor: 18.959

4.  Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.

Authors:  Prathima Anandi; Xin Tian; Sawa Ito; Pawel Muranski; Puja D Chokshi; Noelle Watters; Upneet Chawla; Nancy Hensel; David F Stroncek; Minoo Battiwalla; A John Barrett
Journal:  Cytotherapy       Date:  2017-04-07       Impact factor: 5.414

5.  Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells.

Authors:  Y Reisner; N Kapoor; D Kirkpatrick; M S Pollack; B Dupont; R A Good; R J O'Reilly
Journal:  Lancet       Date:  1981-08-15       Impact factor: 79.321

6.  Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

Authors:  Wei Li; Liangyi Liu; Aurelie Gomez; Jilu Zhang; Abdulraouf Ramadan; Qing Zhang; Sung W Choi; Peng Zhang; Joel K Greenson; Chen Liu; Di Jiang; Elizabeth Virts; Stephanie L Kelich; Hong Wei Chu; Ryan Flynn; Bruce R Blazar; Helmut Hanenberg; Samir Hanash; Sophie Paczesny
Journal:  JCI Insight       Date:  2016-05-05

7.  Donor APCs are required for maximal GVHD but not for GVL.

Authors:  Catherine C Matte; Jinli Liu; James Cormier; Britt E Anderson; Ioanna Athanasiadis; Dhanpat Jain; Jennifer McNiff; Warren D Shlomchik
Journal:  Nat Med       Date:  2004-08-01       Impact factor: 53.440

8.  TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia.

Authors:  M Maschan; L Shelikhova; M Ilushina; E Kurnikova; E Boyakova; D Balashov; M Persiantseva; Y Skvortsova; A Laberko; Y Muzalevskii; A Kazachenok; S Glushkova; V Bobrynina; V Kalinina; Y Olshanskaya; D Baidildina; G Novichkova; A Maschan
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

9.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

Authors:  Mark T Vander Lugt; Thomas M Braun; Samir Hanash; Jerome Ritz; Vincent T Ho; Joseph H Antin; Qing Zhang; Chee-Hong Wong; Hong Wang; Alice Chin; Aurélie Gomez; Andrew C Harris; John E Levine; Sung W Choi; Daniel Couriel; Pavan Reddy; James L M Ferrara; Sophie Paczesny
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

10.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

Authors:  Marcelo C Pasquini; Steven Devine; Adam Mendizabal; Lindsey R Baden; John R Wingard; Hillard M Lazarus; Frederick R Appelbaum; Carolyn A Keever-Taylor; Mary M Horowitz; Shelly Carter; Richard J O'Reilly; Robert J Soiffer
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.